Identification of the sAPRIL binding peptide and its growth inhibition effects in the colorectal cancer cells

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  He, Xiao Qing ^a,b   Guan, Jing ^a,c   Liu, Fang ^a   Li, Jing ^a   He, Mei Rong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Wuzhou People's Hospital   (China)

^c Army Reserve Anti aircraft Artillery Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL BINDING PEPTIDE; APRIL PROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; LOW DRUG DOSE; MOUSE; NONHUMAN; PHAGE DISPLAY; TUMOR XENOGRAFT; CHEMISTRY; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PEPTIDES; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926512663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120564     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300. doi: 10.3322/caac.20073 PMID: 20610543
2. Lopez-Fraga M, Fernandez R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep. 2001; 2: 945-951. PMID: 11571266
3. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003; 21: 231-264. PMID: 12427767
4. Medema JP, Planelles-Carazo L, Hardenberg G, Hahne M. The uncertain glory of APRIL. Cell Death Differ. 2003; 10: 1121-1125. PMID: 14502235
5. Stein JV, Lopez-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, et al. APRIL modulates B and T cell immunity. J Clin Invest. 2002; 109: 1587-1598. PMID: 12070306
6. Wang F, Chen L, Ding W, Wang G, Wu Y, Wang J, et al. Serum APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Lab Med. 2011; 49: 1715-1719. doi: 10.1515/CCLM.2011.608 PMID: 21612541
7. Pelekanou V, Notas G, Theodoropoulou K, Kampa M, Takos D, Alexaki VI, et al. Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas. Anal Cell Pathol (Amst). 2011; 34: 49-60. doi: 10.3233/ACP-2011-0001 PMID: 21483105
8. Munari F, Lonardi S, Cassatella MA, Doglioni C, Cangi MG, Amedei A, et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood. 2011; 117: 6612-6616. doi: 10.1182/blood-2010-06-293266 PMID: 21527528
9. Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC cancer. 2009; 9: 83. doi: 10.1186/1471-2407-9-83 PMID: 19291294
10. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998; 188: 1185-1190. PMID: 9743536
11. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005; 12: 637-648. PMID: 15846369
12. Lascano V, Zabalegui LF, Cameron K, Guadagnoli M, Jansen M, Burggraaf M, et al. The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ. 2012; 19: 1826-1835. doi: 10.1038/cdd.2012.68 PMID: 22705846
13. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, Loudon M, et al. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC cancer. 2009; 9: 434. doi: 10.1186/1471-2407-9-434 PMID: 20003335
14. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004; 172: 3268-3279. PMID: 14978135
15. Wang F, Ding W, Wang J, Jing R, Wang X, Cong H, et al. Identification of microRNA-target interaction in APRIL-knockdown colorectal cancer cells. Cancer Gene Ther. 2011; 18: 500-509. doi: 10.1038/cgt.2011.19 PMID: 21597503
16. Xia XZ, Treanor J, Senaldi G, Khare SD, Boone T, Kelley M, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med. 2000; 192: 137-143. PMID: 10880535
17. Gras MP, Laabi Y, Linares-Cruz G, Blondel MO, Rigaut JP, Brouet JC, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995; 7: 1093-1106. PMID: 8527407
18. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004; 103: 689-694. PMID: 14512299
19. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev. 2008; 19: 263-276. doi: 10.1016/j.cytogfr.2008.04.006 PMID: 18514565
20. Spillmann D. Heparan sulfate: anchor for viral intruders? Biochimie. 2001; 83: 811-817. PMID: 11530214
21. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004; 103: 679-688. PMID: 14504101
22. Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, et al. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ. 2001; 8: 403-410. PMID: 11550092
23. Quinn J, Glassford J, Percy L, Munson P, Marafioti T, Rodriguez-Justo M, et al. APRIL promotes cellcycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood. 2011; 117: 890-901. doi: 10.1182/blood-2010-01-264424 PMID: 20709908
24. Wang F, Chen L, Ni H, Wang G, Ding W, Cong H, et al. APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-beta1/ERK signaling pathway in human colorectal cancer cells. Mol Cell Biochem. 2013; 383: 179-189. doi: 10.1007/s11010-013-1766-8 PMID: 23867993
25. Wang G, Wang F, Ding W, Wang J, Jing R, Li H, et al. APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. PloS one. 2013; 8: e55298. doi: 10.1371/journal.pone.0055298 PMID: 23383143
26. Wang J, Ding W, Sun B, Jing R, Huang H, Shi G, et al. Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA. Mol Cell Biochem. 2012; 363: 1-10. doi: 10.1007/s11010-011-1151-4 PMID: 22170570
27. Ding W, Wang J, Sun B, Ju S, Yuan H, Wang X, et al. APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem. 2009; 42: 1694-1698. doi: 10.1016/j. clinbiochem.2009.06.019 PMID: 19573525
28. Guan J, Sun AM, Wang LH, He MR. [Lentivirus-mediated RNA interference suppresses APRIL expression and enhances chemosensitivity in colorectal cancer cells]. Nan fang yi ke da xue xue bao. 2011; 31: 1600-1604. PMID: 21945777
29. Gao Q, Li Q, Xue Z, Wu P, Yang X. In vitro and in vivo evaluation of a humanized anti-APRIL antibody. Curr Mol Med. 2013; 13: 464-465. PMID: 23331019
30. Bonci D, Musumeci M, Coppola V, Addario A, Conticello C, Hahne M, et al. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica. 2008; 93: 1899-1902. doi: 10.3324/haematol.13035 PMID: 18838478
31. Dai S, Zheng Y, Chen B, Gao M, Zhang Y, Zhang L, et al. Two Gln187 mutants of human soluble APRIL inhibit proliferation of lung carcinoma A549 cells. Acta biochimica Polonica. 2009; 56: 703-710. PMID: 19997650
32. Tu X, Zhuang J, Wang W, Zhao L, Zhao J, Deng C, et al. Screening and identification of a renal carcinoma specific peptide from a phage display peptide library. J Exp Clin Cancer Res. 2011; 30: 105. doi: 10.1186/1756-9966-30-105 PMID: 22071019
33. Liu W, MacKay JA, Dreher MR, Chen M, McDaniel JR, Simnick AJ, et al. Injectable intratumoral depot of thermally responsive polypeptide-radionuclide conjugates delays tumor progression in a mouse model. J Control Release. 2010; 144: 2-9. doi: 10.1016/j.jconrel.2010.01.032 PMID: 20117157
34. Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 2005; 11: 713-726. PMID: 16138387
35. Janin YL. Peptides with anticancer use or potential. Amino acids. 2003; 25: 1-40. PMID: 12836056
36. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers. 2002; 66: 184-199. PMID: 12385037
37. Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diabetes Sci Technol. 2011; 5: 1521-1528. PMID: 22226275
38. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, et al. Molecular engineering of short half-life small peptides (VIP, alphaMSH and gamma(3)MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum Dis. 2012; 71: 143-149. doi: 10.1136/annrheumdis-2011-200100 PMID: 21998117
39. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 1991; 354: 82-84. PMID: 1944576
40. Rastelli L, Valentino ML, Minderman MC, Landin J, Malyankar UM, Lescoe MK, et al. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Int J Oncol. 2011; 39: 401-408. doi: 10.3892/ijo.2011.1040 PMID: 21567086
41. Corti A, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol. 2011; 12: 1128-1134. PMID: 21470145
42. Moller I, Thomas A, Geyer H, Schanzer W, Thevis M. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun Mass Spectrom. 2011; 25: 2115-2123. doi: 10.1002/rcm.5109 PMID: 21710591
43. Cazal CM, Choosang K, Severino VG, Soares MS, Sarria AL, Fernandes JB, et al. Evaluation of effect of triterpenes and limonoids on cell growth, cell cycle and apoptosis in human tumor cell line. Anticancer Agents Med Chem. 2010; 10: 769-776. PMID: 21269253
44. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell. 1993; 74: 777-779. PMID: 8104100
45. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000; 192: 1677-1684. PMID: 11104810
46. Wang F, Chen L, Mao ZB, Shao JG, Tan C, Huang WD. Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep. 2008; 20: 135-139. PMID: 18575728
47. Wang GH, Lu MH, Wang JC, Wang F, Ding WF, Wang YG, et al. [Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis]. Zhonghua zhong liu za zhi. 2013; 35: 249-255. doi: 10.3760/cma.j.issn.0253-3766.2013.04.003 PMID: 23985251
48. Cui JW, Li Y, Wang C, Yao C, Li W. Knockdown of a proliferation-inducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev. 2012; 13: 633-636. PMID: 22524837
49. Norikura T, Kojima-Yuasa A, Shimizu M, Huang X, Xu S, Kametani S, et al. Mechanism of growth inhibitory effect of Blumea balsamifera extract in hepatocellular carcinoma. Biosci Biotechnol Biochem. 2008; 72: 1183-1189. PMID: 18460811